In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...

The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...

BioNTech SE plans to halt operations at several manufacturing sites, affecting as many as 1,860 jobs, due to dwindling demand ...

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing. There have been over 40 rounds of layoffs announced this year as of April 30, compared to more ...

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, ...

BioNTech is planning site closures affecting up to 1,860 jobs and will buy back $1 billion in shares after announcing the ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American ...

BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Germany s BioNTech said Tuesday it will halt operations at several sites, in a move affecting up to 1,860 jobs, as sales of ...

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...